US6015541A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Radioactive embolizing compositions
Assignee: Covidien LP
•
Filing: 1997-11-03
•
Granted: 2000-01-18
•
Expires: 2017-11-03
Abstract
Abstract Disclosed are novel radioactive compositions which are particularly suited for treating solid mass tumors via catheter delivery.
Inventors
- 👤 Richard J. Greff
- 👤 George Wallace
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 17:22
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/06; A61K51/12; A61K51/1217; A61P; A61P35/00; A61K2121/00
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
128 words
A composition suitable for treating a solid mass tumor in a mammal which composition comprises: (a) a non-crosslinked, biocompatible, non-biodegradable polymer which polymer is insoluble in blood; (b) a biocompatible solvent which is an organic material liquid at least at body temperature of the mammal and which solubilizes said polymer with the proviso that when said solvent comprises water, the amount of water employed is sufficiently small that the dissolved polymer precipitates upon contact with the blood; and (c) from about 0.1 to about 25 weight percent of a water insoluble radioisotope having from a radioactive content of from about 0.5 microcurie to about 100 millicuries with the proviso that when theradioisotope is either water soluble or water reactable, said isotope is used as a water insoluble salt.
Claim 2
Dependent Claim
128 words
A composition suitable for treating a solid mass tumor in a mammal which composition comprises: (a) a non-crosslinked, biocompatible, non-biodegradable polymer which polymer is insoluble in blood; (b) a biocompatible solvent which is an organic material liquid at least at body temperature of the mammal and which solubilizes said polymer with the proviso that when said solvent comprises water, the amount of water employed is sufficiently small that the dissolved polymer precipitates upon contact with the blood; and (c) from about 0.1 to about 25 weight percent of a water insoluble radioisotope having from a radioactive content of from about 0.5 microcurie to about 100 millicuries with the proviso that when theradioisotope is either water soluble or water reactable, said isotope is used as a water insoluble salt.
Claim 3
Dependent Claim
21 words
The composition according to claim 1 wherein said biocompatible solvent is selected from the group consisting of dimethylsulfoxide, ethanol and acetone.
Claim 4
Dependent Claim
12 words
The composition according to claim 2 wherein said biocompatible solvent is dimethylsulfoxide.
Claim 5
Dependent Claim
41 words
The composition according to claim 1 wherein said non-biodegradable biocompatible polymer is selected from the group consisting of cellulose acetates, ethylene vinyl alcohol copolymers, hydrogels, polyacrylonitrile, polyvinylacetate, cellulose acetate butyrate, nitrocellulose, copolymers of urethane/carbonate, copolymers of styrene/maleic acid, and mixtures thereof.
Claim 6
Dependent Claim
19 words
The composition according to claim 4 wherein said non-biodegradable biocompatible polymer is a copolymer of ethylene and vinyl alcohol.
Claim 7
Dependent Claim
79 words
The composition according to claim 1 wherein said radioisotope is selected from the group consisting of 90 yttrium, 192 iridium, 198 gold, 125 iodine, 137 cesium, 60 cobalt, 55 cobalt, 56 cobalt, 57 cobalt, 57 magnesium, 55 iron, 32 phosphorus, 90 strontium, 81 rubidium, 206 bismuth, 67 gallium, 77 bromine, 129 cesium, 73 selenium, 72 selenium, 72 arsenic, 103 palladium, 203 lead, 111 indium, 52 iron, 167 thulium, 57 nickel, 62 zinc, 61 copper, 201 thallium, and 123 iodine.
Claim 8
Dependent Claim
13 words
The composition according to claim 1 which further comprises a non-radioactive contrast agent.
Claim 9
Dependent Claim
14 words
The composition according to claim 7 wherein said non-radioactive contrast agent is water soluble.
Claim 10
Dependent Claim
28 words
The composition according to claim 8 wherein said water soluble non-radioactive contrast agent is selected from the group consisting of metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine.
Claim 11
Dependent Claim
14 words
The composition according to claim 7 wherein said non-radioactive contrast agent is water insoluble.
Claim 12
Dependent Claim
22 words
The composition according to claim 10 wherein said water insoluble contrast agent is tantalum, tantalum oxide, barium sulfate, tungsten, gold and platinum.
Claim 13
Independent Claim
212 words
A method for embolizing a blood vessel leading to or in a solid mass tumor in a mammal and causing necrosis to a portion of said solid mass tumor which method comprises: (a) identifying a blood vessel in said mammal which leads to or is in the solid mass tumor; (b) injecting a sufficient amount of an embolic composition comprising: (i) a non-crosslinked, biocompatible, non-biodegradable polymer which polymer is insoluble in blood; (ii) a biocompatible solvent which is an organic material liquid at least at body temperature of the mammal and which solubilizes said polymer with the proviso that when said solvent comprises water, the amount of water employed is sufficiently small that the dissolved polymer precipitates upon contact with the blood; and (iii) from about 0.1 to about 25 weight percent of a water insoluble radioiotope having from a radioactive content of from about 0.5 microcurie to about 100 millicuries with the proviso that when the radioisotope is either water soluble or water reactable, said isotope is used as a water insoluble salt into said blood vessel under conditions wherein a precipitate is formed which embolizes the blood vessel and further wherein the radioisotope is employed in an amount effective to cause necrosis of at least a portion of said tumor.
Claim 14
Independent Claim
212 words
A method for embolizing a blood vessel leading to or in a solid mass tumor in a mammal and causing necrosis to a portion of said solid mass tumor which method comprises: (a) identifying a blood vessel in said mammal which leads to or is in the solid mass tumor; (b) injecting a sufficient amount of an embolic composition comprising: (i) a non-crosslinked, biocompatible, non-biodegradable polymer which polymer is insoluble in blood; (ii) a biocompatible solvent which is an organic material liquid at least at body temperature of the mammal and which solubilizes said polymer with the proviso that when said solvent comprises water, the amount of water employed is sufficiently small that the dissolved polymer precipitates upon contact with the blood; and (iii) from about 0.1 to about 25 weight percent of a water insoluble radioiotope having from a radioactive content of from about 0.5 microcurie to about 100 millicuries with the proviso that when the radioisotope is either water soluble or water reactable, said isotope is used as a water insoluble salt into said blood vessel under conditions wherein a precipitate is formed which embolizes the blood vessel and further wherein the radioisotope is employed in an amount effective to cause necrosis of at least a portion of said tumor.
Claim 15
Dependent Claim
21 words
The method according to claim 12 wherein said biocompatible solvent is selected from the group consisting of dimethylsulfoxide, ethanol and acetone.
Claim 16
Dependent Claim
12 words
The method according to claim 13 wherein said biocompatible solvent is dimethylsulfoxide.
Claim 17
Dependent Claim
41 words
The method according to claim 12 wherein said non-biodegradable biocompatible polymer is selected from the group consisting of cellulose acetates, ethylene vinyl alcohol copolymers, hydrogels, polyacrylonitrile, polyvinylacetate, cellulose acetate butyrate, nitrocellulose, copolymers of urethane/carbonate, copolymers of styrene/maleic acid, and mixtures thereof.
Claim 18
Dependent Claim
19 words
The method according to claim 15 wherein said non-biodegradable biocompatible polymer is a copolymer of ethylene and vinyl alcohol.
Claim 19
Dependent Claim
78 words
The method according to claim 12 wherein said radioisotope is selected from the group consisting of 90 yttrium, 192iridium, 198 gold, 125 iodine, 137 cesium, 60 cobalt, 55 cobalt, 56 cobalt, 57 cobalt, 57 magnesium, 55 iron, 32 phosphorus, 90 strontium, 81 rubidium, 206 bismuth, 67 gallium, 77 bromine, 129 cesium, 73 selenium, 72 selenium, 72 arsenic, 103 palladium, 203 lead, 111 indium, 52 iron, 167 thulium, 57 nickel, 62 zinc, 61 copper, 201 thallium, and 123 iodine.
Claim 20
Dependent Claim
15 words
The method according to claim 12 wherein said composition further comprises a non-radioactive contrast agent.
Claim 21
Dependent Claim
14 words
The method according to claim 17 wherein said non-radioactive contrast agent is water soluble.
Claim 22
Dependent Claim
28 words
The method according to claim 18 wherein said water soluble non-radioactive contrast agent is selected from the group consisting of metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine.
Claim 23
Dependent Claim
14 words
The method according to claim 17 wherein said non-radioactive contrast agent is water insoluble.
Claim 24
Dependent Claim
22 words
The method according to claim 21 wherein said water insoluble contrast agent is tantalum, tantalum oxide, barium sulfate, tungsten, gold and platinum.
Claim 25
Independent Claim
179 words
A method for causing necrosis to a portion of a solid mass tumor which method comprises: (a) identifying a solid mass tumor in a mammal; (b) injecting a sufficient amount of an embolic composition comprising: (i) a non-crosslinked, biocompatible, non-biodegradable polymer which polymer is insoluble in blood; (ii) a biocompatible solvent which is an organic material liquid at least at body temperature of the mammal and which solubilizes said polymer with the proviso that when said solvent comprises water, the amount of water employed is sufficiently small that the dissolved polymer precipitates upon contact with the blood; and (iii) from about 0.1 to about 25 weight percent of a water insoluble radioisotope having from a radioactive content of from about 0.5 microcurie to about 100 millicuries with the proviso that when the radioisotope is either water soluble or water reactable, said isotope is used as a water insoluble salt into said tumor under conditions wherein a precipitate is formed wherein the radioisotope is employed in an amount effective to cause necrosis of at least a portion of said tumor.
Claim 26
Independent Claim
179 words
A method for causing necrosis to a portion of a solid mass tumor which method comprises: (a) identifying a solid mass tumor in a mammal; (b) injecting a sufficient amount of an embolic composition comprising: (i) a non-crosslinked, biocompatible, non-biodegradable polymer which polymer is insoluble in blood; (ii) a biocompatible solvent which is an organic material liquid at least at body temperature of the mammal and which solubilizes said polymer with the proviso that when said solvent comprises water, the amount of water employed is sufficiently small that the dissolved polymer precipitates upon contact with the blood; and (iii) from about 0.1 to about 25 weight percent of a water insoluble radioisotope having from a radioactive content of from about 0.5 microcurie to about 100 millicuries with the proviso that when the radioisotope is either water soluble or water reactable, said isotope is used as a water insoluble salt into said tumor under conditions wherein a precipitate is formed wherein the radioisotope is employed in an amount effective to cause necrosis of at least a portion of said tumor.
References Cited (Backward Citations)
US3527224A
Cited
US3591676A
Cited
US4268495A
Cited
US4795741A
Cited
US4938763A
Cited
US4938763B1
Cited
US5514379A
Cited
US5443454A
Cited
US5580568A
Cited
US5667767A
Cited
WO1997007055A1
Cited
US5695480A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-01-17 | 2003-07-19 | 2004-01-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-01-17 | 2007-07-19 | 2008-01-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-01-17 | 2011-07-19 | 2012-01-18 | $7700.00 | Window Closed / Lapsed |